VCELVericel Corporation
Vericel Corporation (VCEL) is a biotechnology company focused on developing and commercializing advanced therapies for burn care and other dermatological conditions. The company’s next catalyst is November 18, 2026 — Vericel to present at the Stephens Annual Investment Conference, where it will test the market’s appetite for its pipeline progress and strategic direction.
- Revenue grew 16.5% YoY to $298.76M in 2026, with a net margin of 4.1% (TTM).
- Debt-to-equity is a mere 0.01x, reflecting strong balance sheet discipline.
- Shareholders’ equity stands at $354.64M, with diluted EPS of $0.27.
The Read
Vericel's stock fell nearly 9% after missing aggressive 2026 guidance, then sold off another 6% following strong Q1 results due to 'sell the news' sentiment, but rallied 7%.
The schedule
- Wed18Nov
The presentation will test Vericel's ability to communicate its clinical and commercial progress to institutional investors, potentially boosting investor confidence and share price. This event will focus on recent trial results and strategic direction.
- Sat26Dec
This update will test Vericel's ability to provide clarity on its Burn Care product's clinical and commercial performance, potentially influencing investor sentiment and stock movement.
- Fri1Jan
The Investor FAQs will test Vericel's ability to address investor concerns and provide clarity on its strategic priorities, which could influence market perception and stock price.
- Wed24Feb
The earnings release will test whether Vericel can maintain its guidance and deliver on its clinical and commercial momentum, following a recent positive trial readout. This differs from the last print where the guidance cut led to a bearish outcome.
- Wed26May
This earnings release will test the company's ability to sustain its recent clinical and commercial progress, with a focus on revenue growth and margin expansion. The outcome will be influenced by the guidance provided and the market's reception of its pipeline updates.
- Wed25Aug
The Q2 earnings release will test Vericel's ability to deliver on its long-term growth strategy, particularly in light of recent clinical and regulatory updates. This will be a critical test of its ability to convert clinical momentum into revenue and cash flow.
- Fri26Nov
This earnings release will test Vericel's ability to maintain its recent momentum and deliver on its long-term growth strategy. The outcome will be influenced by the guidance provided and the market's reception of its pipeline updates.
Past
- Fri23Oct
Actual outcome: Bull · $57.89 at outcome
VCEL experienced a significant upward move likely driven by positive clinical trial results, indicating promising efficacy or safety data. The move suggests the company's therapeutic candidate met or exceeded expectations, potentially advancing to the next phase of development. This would have increased investor confidence and valuation expectations. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +28.4% from 2026-10-23 to 2026-11-09 (~3.2σ vs typical 10d vol). Target evaluation date 2026-11-10 (not yet reached as of 2026-11-09). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-10: +35.8% from 2026-10-26 (~4.0σ). Target date 2026-11-01 reached; move through 2026-11-10 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-11: +36.3% from 2026-10-27 (~4.0σ). Target date 2026-11-01 reached; move through 2026-11-11 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-12: +45.0% from 2026-10-28 (~5.0σ). Target date 2026-11-01 reached; move through 2026-11-12 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-13: +33.8% from 2026-10-29 (~3.9σ). Target date 2026-11-01 reached; move through 2026-11-13 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-16: +41.4% from 2026-10-30 (~4.8σ). Target date 2026-11-01 reached; move through 2026-11-16 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-17: +41.9% from 2026-11-02 (~4.8σ). Target date 2026-11-01 reached; move through 2026-11-17 observed.
VCEL experienced a significant upward move likely driven by positive clinical trial results, indicating promising efficacy or safety data. The move suggests the company's therapeutic candidate met or exceeded expectations, potentially advancing to the next phase of development. This would have increased investor confidence and valuation expectations. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +28.4% from 2026-10-23 to 2026-11-09 (~3.2σ vs typical 10d vol). Target evaluation date 2026-11-10 (not yet reached as of 2026-11-09). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-10: +35.8% from 2026-10-26 (~4.0σ). Target date 2026-11-01 reached; move through 2026-11-10 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-11: +36.3% from 2026-10-27 (~4.0σ). Target date 2026-11-01 reached; move through 2026-11-11 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-12: +45.0% from 2026-10-28 (~5.0σ). Target date 2026-11-01 reached; move through 2026-11-12 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-13: +33.8% from 2026-10-29 (~3.9σ). Target date 2026-11-01 reached; move through 2026-11-13 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-16: +41.4% from 2026-10-30 (~4.8σ). Target date 2026-11-01 reached; move through 2026-11-16 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-11-17: +41.9% from 2026-11-02 (~4.8σ). Target date 2026-11-01 reached; move through 2026-11-17 observed.
- Tue29Sep
Actual outcome: Mixed · $40.30 at outcome
Vericel's stock fell 0.8% immediately after the event, but the broader market reaction and subsequent price action pushed it past the bull target. The event likely signaled increased visibility and potential partnership opportunities, which drove the stock higher in the following weeks. The price surge past the bull target suggests investor confidence in the company's strategic positioning and future growth prospects.
Morgan Stanley will host Vericel at a healthcare conference Sept. 15
- Tue15Sep
Actual outcome: Bull · $40.61 at outcome
Vericel's presentation at Morgan Stanley highlighted positive strategic developments, including strong pipeline progress and partnership opportunities, which reinforced investor confidence. These factors drove the stock toward the bull target despite a flat price reaction, as the market focused on long-term growth potential rather than short-term results.
Vericel Presents at Morgan Stanley
- Thu6Aug
Actual outcome: Bear · $42.10 at outcome
The stock fell 5.9% following the Q3 2026 earnings release, despite the EPS beating expectations by 0.0%. The price action suggests a bearish reaction, likely due to underwhelming guidance or other negative factors not explicitly mentioned in the results, which overshadowed the earnings beat.
Q3 2026 Earnings Release
- Thu7May
Actual outcome: Bear · $33.03 at outcome
Vericel reported a strong Q1, beating estimates with a narrower-than-expected loss of $0.12 per share and a 30% year-over-year revenue increase to $68.4 million, driven by robust MACI and Burn Care growth. The company also raised its full-year 2026 financial guidance. Despite these positive fundamentals, the stock fell 6.0% by the outcome date, experiencing a 'sell the news' reaction as the market had likely already priced in the strong growth expectations.
- Wed15Apr
Actual outcome: Mixed · $34.37 at outcome
Vericel did not release any material updates regarding NexoBrid payer coverage or formulary wins during the target window. In the absence of a clear fundamental catalyst, the stock experienced a mild 2.8% decline, remaining range-bound between the bull and bear targets.
- Tue10Mar
Actual outcome: Bear · $32.53 at outcome
Vericel reported in-line EPS of $0.46, exactly meeting analyst estimates. However, with the stock trading at a premium 85.8x P/E multiple heading into the print, the market required a flawless NexoBrid commercial ramp and an earnings beat to justify the valuation. The lack of an upside surprise failed to satisfy these high expectations, causing the stock to sell off toward the bear floor.
- Thu26Feb
Actual outcome: Bear · $34.39 at outcome
Vericel matched Q4 EPS estimates and reported solid 21% MACI revenue growth, but the results failed to provide the aggressive 2026 guidance required to justify the stock's high valuation multiples. The lack of a significant revenue beat or a more robust NexoBrid commercial ramp-up triggered a sell-off, driving the price down nearly 9% toward the $32.00 bear floor by the run date.